Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
NEWTON, Mass. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) is scheduled to review data supporting the
View HTML
Toggle Summary Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
-- XPOVIO is the First and Only Nuclear Export Inhibitor Approved by the FDA -- -- XPOVIO is the First and Only Prescription Medicine Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and an
View HTML
Toggle Summary Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application
- PDUFA Action Date Extended by Three Months to July 6, 2019 - - FDA Has Requested Additional Existing Information for Review - NEWTON, Mass. , March 14, 2019 /PRNewswire/ --  Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the U.S.
View HTML
Toggle Summary Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma
NEWTON, Mass. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to discuss the New Drug Application (NDA) for
View HTML
Toggle Summary Karyopharm Announces Publication of XPOVIO™ (Selinexor) Phase 2b STORM Study Results in The New England Journal of Medicine
-- XPOVIO was Recently Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and an Anti-CD38 Monoclonal Antibody -- -- In STORM, XPOVIO Achieved a 26% Overall Response Rate, 8.6 Month Median Overall
View HTML
Toggle Summary Karyopharm Announces Results of Clinical Studies Investigating Selinexor to be Presented at the European Hematology Association 2019 Annual Meeting
-- Oral Presentation Highlighting Updated Data from the Phase 1b/2 STOMP Study Arm Evaluating Selinexor and Dexamethasone in Combination with Darzalex® in Patients with Relapsed or Refractory Multiple Myeloma -- -- Two Posters Highlighting Updated Data from the STOMP Arms Evaluating Selinexor and
View HTML
Toggle Summary Karyopharm Announces Submission of Marketing Authorization Application to the European Medicines Agency for Selinexor for the Treatment of Patients with Penta-Refractory Multiple Myeloma
-- Selinexor Marketing Authorization Application to be Reviewed Under Accelerated Assessment -- NEWTON, Mass. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has submitted a Marketing Authorization
View HTML
Toggle Summary Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting
-- Updated Results from the Pomalyst® and Kyprolis® Arms of the Phase 1b/2 STOMP Study Evaluating Selinexor in Combination with Other Approved Myeloma Therapies in Relapsed or Refractory Multiple Myeloma to be Highlighted -- -- Other Key Presentations Include New Data from the STOMP Revlimid® Arm
View HTML
Toggle Summary Karyopharm Announces XPOVIO™ (Selinexor) Presentations at the 17th International Myeloma Workshop
NEWTON, Mass., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that five abstracts highlighting clinical data for XPOVIO™ (selinexor) will be presented at the 17 th International Myeloma Workshop (IMW) taking
View HTML
Toggle Summary Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million
-- Investment Expected to Extend Karyopharm’s Cash Runway into Middle of 2021 -- NEWTON, Mass. , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced its entry into a royalty agreement with HealthCare Royalty
View HTML